How Bayer AG Makes Money

Bayer AG generates revenue through three distinct but interrelated business divisions, each with fundamentally different economic characteristics, margin profiles, and competitive dynamics. The Pharmaceuticals Division contributed $19.8 billion (38.9% of group sales) in 2024, making it the second-largest revenue contributor but historically the highest-margin and most strategically valuable segment. Pharmaceutical revenues come from prescription drug sales to healthcare providers, hospitals, and pharmacies worldwide, supplemented by license fees from partnership arrangements. The division's product portfolio spans oncology (Nubeqa/darolutamide, $1.7 billion), cardiovascular and renal (Xarelto/rivaroxaban, declining due to generics; Kerendia/finerenone, growing rapidly at +67%), ophthalmology (Eylea/aflibercept, sustained by 8mg formulation launch), radiology contrast agents, women's health (Mirena intrauterine systems), and hematology. The business model is classic branded pharmaceutical: high upfront R&D investment ($6.8 billion group-wide in 2024, with Pharmaceuticals consuming the majority), patent-protected pricing power during exclusivity periods, and steep revenue cliffs upon generic entry. Xarelto exemplifies this model's vulnerability—once generating over $5.5 billion annually, it faced patent expiry and competitive pressure from generics that reduced sales markedly in 2024, particularly in Europe and Canada where generic entry was most aggressive. License revenues from the U.S., where Johnson & Johnson subsidiary Janssen markets Xarelto, remained at prior-year levels, providing a partial buffer. The gross margin for Pharmaceuticals was approximately 74.6% in 2024 (implied from cost of goods sold of $5.0 billion on $19.8 billion sales), though this is compressed by license fee payments to partners and the product mix shift toward newer, lower-margin launches. The EBITDA margin before special items was 26.0%, down 2.7 percentage points from 2023, reflecting increased selling expenses for new product launches, higher R&D investments in cell and gene therapy, and the Xarelto generic erosion. The Crop Science Division generated $24.3 billion (47.8% of group sales) in 2024, making it the largest revenue contributor by absolute euros but the most volatile and lowest-margin segment. Crop Science revenues derive from three product categories: crop protection chemicals (herbicides, fungicides, insecticides), seeds and traits (genetically modified and conventional seeds), and digital agriculture solutions. The glyphosate-based herbicide business, inherited from Monsanto, remains the largest single product line but is in structural decline—glyphosate sales fell 19% year-over-year in 2024 due to price competition from Chinese generic manufacturers and normalized shipping patterns after pandemic-era supply chain disruptions. Corn Seed & Traits showed strong growth, offsetting some glyphosate weakness, while the soybean and cotton seed businesses faced pricing pressure. The Crop Science business model is fundamentally different from pharmaceuticals: it is commodity-like, with prices set by global agricultural commodity markets, weather patterns, and farmer planting decisions rather than patent exclusivity. The gross margin is lower than pharmaceuticals, and the EBITDA margin before special items was 19.4% in 2024, unchanged from 2023 but significantly below pharmaceutical levels. The division requires heavy capital investment in R&D (seed trait development, new chemistry discovery) and manufacturing (the Soda Springs, Idaho facility for glyphosate raw materials, the Monheim R&D campus expansion). The five-year framework announced in 2024 aims to improve Crop Science profitability through portfolio streamlining, cost reduction, and strategic pricing actions, but execution remains uncertain. The Consumer Health Division contributed $6.4 billion (12.6% of group sales) in 2024, with 1.9% currency-adjusted growth. This division markets over-the-counter medications, nutritional supplements, and dermatology products under brands including Aspirin, Aleve, Claritin, Bepanthen, and Coppertone. The business model is consumer-packaged-goods-like: lower margins than pharmaceuticals but more stable, recurring revenues with less patent cliff risk. The EBITDA margin before special items was 23.3% in 2024, down 0.1 percentage points. Consumer Health faces competitive pressure from private-label alternatives, retailer consolidation (especially in the U.S. where Walmart and Amazon dominate), and category-specific challenges such as a soft cold and flu season that reduced allergy and cold product sales. The division has pursued portfolio optimization, divesting non-core brands and focusing on high-growth categories like dermatology and digestive health, which outperformed in 2024. The corporate overhead and reconciliation segment, which includes shared services, corporate R&D, and central functions, reported sales of $377.1 million and EBITDA before special items of negative $316.1 million. This overhead is substantial and reflects the complexity of managing three disparate businesses under one corporate umbrella—a structural inefficiency that Anderson's DSO model aims to address by pushing decision-making closer to products and customers. The overall group cost structure reveals the scale of Bayer's operational challenge. Cost of goods sold increased 7.7% to $23.2 billion in 2024, with the ratio to total sales rising to 45.6% from 41.5% in 2023—an alarming margin compression driven by inflation, product mix shifts, and increased manufacturing costs. Selling expenses rose 7.1% to $14.6 billion, reflecting investments in new product launches. R&D expenses increased 15.6% to $6.8 billion, with the increase driven by early-stage research investments and cell and gene therapy programs. General administration expenses rose 4.9% to $2.8 billion. Personnel expenses increased 16.5% to $13.6 billion, mainly due to restructuring program costs and incentive program expenses. The net result is a company where operational costs are growing faster than revenues, squeezing profitability even before litigation and special charges are considered. The revenue geography provides additional insight. Europe/Africa/Middle East contributed $24.0 billion (47.2% of group sales), North America $14.6 billion (28.8%), Asia/Pacific $8.1 billion (15.9%), and Latin America $4.1 billion (8.1%). The North American exposure is particularly significant because it concentrates both the highest-margin pharmaceutical sales and the highest-risk litigation exposure. Currency effects were substantial in 2024, with a negative impact of $1.5 billion on reported sales, reflecting euro strength against key emerging market currencies.

Bayer's growth strategy under CEO Bill Anderson rests on four specific, named initiatives with measurable targets: (1) driving Nubeqa and Kerendia to combined peak sales exceeding $5.5 billion by 2028-2030; (2) improving Crop Science EBITDA margins by 300-500 basis points through the five-year framework; (3) achieving $2.2 billion in annual cost savings by 2026 through Dynamic Shared Ownership; and (4) reducing net financial debt to below $27.3 billion to restore strategic flexibility and dividend capacity. The Nubeqa strategy is the highest-priority pharmaceutical initiative. The drug is approved in over 80 markets for non-metastatic castration-resistant prostate cancer and received FDA approval for metastatic castration-sensitive prostate cancer in June 2025. The ARANOTE trial demonstrated 40% risk reduction in high-volume disease and 70% in low-volume disease, with a safety profile showing lower discontinuation rates (6%) than placebo (9%). Bayer is investing heavily in urology and oncology sales forces to capture share from Erleada and Xtandi, particularly as Xtandi approaches patent expiry. The ANZUP adjuvant trial, if positive, could extend Nubeqa into earlier-stage disease where treatment duration is longer and patient volumes are larger. Peak sales estimates have been revised upward from $1.1 billion to above $3.3 billion, with some analysts suggesting $4.4-5 billion is achievable if adjuvant use is approved. The Kerendia strategy targets the intersection of diabetes, chronic kidney disease, and heart failure—a patient population of tens of millions globally. The FINEARTS-HF trial demonstrated benefit in heart failure with preserved ejection fraction, a condition with limited effective therapies. Bayer is building a dedicated cardiovascular sales force and pursuing formulary access with Medicare and commercial payers. The drug's non-steroidal mineralocorticoid receptor antagonist mechanism provides differentiation from SGLT2 inhibitors, and the company is exploring combination regimens that could position Kerendia as a backbone therapy in cardiorenal disease. The Eylea strategy focuses on the 8mg formulation's extended dosing interval as a competitive differentiator against Vabysmo and biosimilars. Bayer is pursuing regulatory approvals for additional indications and geographic markets while managing the transition from the 2mg to 8mg formulation. The radiology business, while smaller, provides stable, recurring revenues with less patent cliff risk and is being expanded through new contrast agent formulations and injection systems. The Crop Science growth strategy is defensive rather than expansive. The five-year framework focuses on portfolio streamlining (exiting low-margin products and geographies), cost reduction (manufacturing optimization, supply chain rationalization), and strategic pricing (value-based pricing for premium seeds and traits). The Monheim R&D campus expansion ($99.2 million investment in 2025) and Dormagen fungicide production expansion ($34.9 million) reflect continued investment in core capabilities. The digital agriculture platform (Climate FieldView) is being enhanced with AI-driven recommendations and expanded to emerging markets. However, the growth outlook is constrained by glyphosate structural decline and regulatory pressure. The Consumer Health strategy focuses on portfolio optimization and geographic expansion. The company has divested non-core brands (including the Care/of personalized vitamin business) and is concentrating on high-growth categories: dermatology (Bepanthen, Coppertone), digestive health (Iberogast, MiraLAX), and allergy (Claritin, Aleve). The division is expanding in emerging markets where OTC penetration is lower and brand recognition provides competitive advantage. The cost reduction strategy through Dynamic Shared Ownership is the most transformative initiative. Anderson has eliminated roughly 50% of management positions, reduced hierarchy layers from as many as 12 to approximately 6-7, and created self-managing teams with decision-making authority closer to customers and products. The $2.2 billion savings target by 2026 is backed by specific actions: headcount reduction (12,000+ cuts already executed), IT simplification, procurement optimization, and manufacturing efficiency. The 2024 annual report notes that 'the number of management positions has been roughly halved' and 'there are now around 11,000 fewer positions overall at Bayer.' The deleveraging strategy is equally specific. The company has guided net financial debt reduction to $34-32.2 billion by end-2025 and is prioritizing debt paydown over dividends and share buybacks. The dividend was cut to $0.1 per share for 2024, and management has signaled that payout ratios will remain minimal until debt targets are achieved. Capital expenditures are being managed tightly, with 2024 capex of $3.0 billion guided to $2.6 billion in 2025. The litigation strategy, while less quantifiable, includes specific tactical elements: individual case management to control verdict sizes, class action settlements to resolve large claim volumes, legislative lobbying for punitive damage caps, and scientific defense of glyphosate safety through regulatory submissions and peer-reviewed publications.